These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 32901840)
1. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells. Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840 [TBL] [Abstract][Full Text] [Related]
2. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137 [TBL] [Abstract][Full Text] [Related]
3. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701 [TBL] [Abstract][Full Text] [Related]
4. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells. Tada M; Sumi T; Tanaka Y; Hirai S; Yamaguchi M; Miyajima M; Niki T; Takahashi H; Watanabe A; Sakuma Y Lung Cancer; 2019 Jul; 133():88-95. PubMed ID: 31200834 [TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers. Dai X; Xia H; Zhou S; Tang Q; Bi F Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107 [TBL] [Abstract][Full Text] [Related]
7. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations. Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236 [TBL] [Abstract][Full Text] [Related]
8. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191 [TBL] [Abstract][Full Text] [Related]
10. CRISPR screens identify a novel combination treatment targeting BCL-X Jung HR; Oh Y; Na D; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Jeong EM; An JY; Sung CO; Lee WS; Lee C; Cho SY Oncogene; 2021 May; 40(18):3287-3302. PubMed ID: 33846570 [TBL] [Abstract][Full Text] [Related]
11. Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells. Geng R; Tan X; Zuo Z; Wu J; Pan Z; Shi W; Liu R; Yao C; Wang G; Lin J; Qiu L; Huang W; Chen S Chin J Cancer; 2017 Jul; 36(1):63. PubMed ID: 28756770 [TBL] [Abstract][Full Text] [Related]
12. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Corcoran RB; Do KT; Kim JE; Cleary JM; Parikh AR; Yeku OO; Xiong N; Weekes CD; Veneris J; Ahronian LG; Mauri G; Tian J; Norden BL; Michel AG; Van Seventer EE; Siravegna G; Camphausen K; Chi G; Fetter IJ; Brugge JS; Chen H; Takebe N; Penson RT; Juric D; Flaherty KT; Sullivan RJ; Clark JW; Heist RS; Matulonis UA; Liu JF; Shapiro GI Clin Cancer Res; 2024 May; 30(9):1739-1749. PubMed ID: 38456660 [TBL] [Abstract][Full Text] [Related]
13. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models. Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339 [TBL] [Abstract][Full Text] [Related]
14. Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in Weisner J; Landel I; Reintjes C; Uhlenbrock N; Trajkovic-Arsic M; Dienstbier N; Hardick J; Ladigan S; Lindemann M; Smith S; Quambusch L; Scheinpflug R; Depta L; Gontla R; Unger A; Müller H; Baumann M; Schultz-Fademrecht C; Günther G; Maghnouj A; Müller MP; Pohl M; Teschendorf C; Wolters H; Viebahn R; Tannapfel A; Uhl W; Hengstler JG; Hahn SA; Siveke JT; Rauh D Cancer Res; 2019 May; 79(9):2367-2378. PubMed ID: 30858154 [TBL] [Abstract][Full Text] [Related]
15. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618 [TBL] [Abstract][Full Text] [Related]
16. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978 [TBL] [Abstract][Full Text] [Related]
17. MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells. Hondo N; Kitazawa M; Koyama M; Nakamura S; Tokumaru S; Miyazaki S; Kataoka M; Seharada K; Soejima Y Cancer Lett; 2023 Jul; 567():216264. PubMed ID: 37336286 [TBL] [Abstract][Full Text] [Related]
18. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma. Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002 [TBL] [Abstract][Full Text] [Related]
19. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771 [No Abstract] [Full Text] [Related]
20. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer. Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711 [No Abstract] [Full Text] [Related] [Next] [New Search]